Acute Myeloid Leukemia (AML) is a disease that occurs when genomic changes alter expression of key genes in myeloid blood cells. These changes cause them to resume an undifferentiated state, proliferate, and maintain growth throughout the body. AML is commonly treated with chemotherapy, but recent efforts to reduce therapy toxicity have focused on drugs that specifically target and inhibit protein products of the cancer’s aberrantly expressed genes. This method has proved difficult for some proteins because of structural challenges or mutations that confer resistance to therapy.
Download count: 0
- Partial requirement for: M.S., Arizona State University, 2017Note typethesis
- Includes bibliographical references (pages 35-37)Note typebibliography
- Field of study: Molecular and cellular biology